Clinical Trial Update: Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer [Phase 3]

View source ↗

Summary

This Phase 3 neoadjuvant trial evaluates pyrotinib in combination with trastuzumab for HER2-positive breast cancer and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: COMPLETED